# Extracellular RNA as a molecular driver and therapeutic target in abdominal aortic aneurysms

**Authors:** Nahla Ibrahim, Hubert Hayden, Gabriel Kurzreiter, Johannes Klopf, Sonja Bleichert, Tyler Artner, Alexander Stiglbauer-Tscholakoff, Wolf Eilenberg, Christoph Neumayer, Christine Brostjan

PMC · DOI: 10.1038/s41598-025-22041-y · Scientific Reports · 2025-10-31

## TL;DR

Extracellular RNA contributes to abdominal aortic aneurysm progression, and targeting it with RNase A reduces inflammation and disease progression.

## Contribution

This study identifies exRNA as a novel therapeutic target for treating abdominal aortic aneurysms.

## Key findings

- ExDNA levels are elevated in AAA patients and mouse models.
- Targeted degradation of exRNA with RNase A significantly reduces aneurysm growth and inflammation.
- RNase A treatment preserves smooth muscle cells and reduces macrophage infiltration and protease expression.

## Abstract

Abdominal aortic aneurysms (AAAs) are characterized by chronic inflammation, matrix degradation and smooth muscle cell (SMC) loss, leading to vessel dilation and rupture, with no current pharmaceutical management options. Since recent studies have highlighted the role of extracellular (ex) nucleic acids in promoting inflammation and tissue damage in cardiovascular conditions, we aimed to characterize the contribution of exDNA and exRNA to AAA pathogenesis and evaluate their potential as therapeutic targets in established disease. Circulating exDNA was elevated in patients and mouse models, while plasma levels of exRNA were not associated with AAA development. When RNase A or DNase I was administered to mice with established disease, the targeted degradation of exRNA, but not exDNA, significantly attenuated aneurysm growth. The RNase A treatment produced systemic anti-inflammatory effects (reduced monocyte/granulocyte count) and showed the potential to improve local vascular conditions by preserving SMC integrity, reducing macrophage infiltration and protease expression. These effects were not observed in DNase I-treated animals. In conclusion, while circulating exDNA showed AAA biomarker potential, targeting exRNA by systemic RNase A treatment effectively mitigated aneurysm progression in established disease through pleiotropic modulation of inflammation and tissue remodeling, presenting a novel and promising therapeutic strategy.

The online version contains supplementary material available at 10.1038/s41598-025-22041-y.

## Linked entities

- **Diseases:** AAA (MONDO:0009279)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Dnase1 (deoxyribonuclease I) [NCBI Gene 13419] {aka DNaseI, Dnl1}, Rnase1 (ribonuclease, RNase A family, 1 (pancreatic)) [NCBI Gene 19752] {aka Rib-1, Rib1}
- **Diseases:** inflammation (MESH:D007249), vessel dilation (MESH:D002311), cardiovascular conditions (MESH:D002318), AAAs (MESH:D017544), AAA (MESH:C565230), aneurysm (MESH:D000783), rupture (MESH:D012421)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12578788/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12578788/full.md

## References

8 references — full list in the complete paper: https://tomesphere.com/paper/PMC12578788/full.md

---
Source: https://tomesphere.com/paper/PMC12578788